Ibrutinib, the world’s first listed BTK inhibitor, has been shown to have a therapeutic effect on coronavirus-induced ALI in the clinic, and it exhibited a mitigating effect on influenza-induced ALI in animal models [82,83]. Here, BTK is linked to influenza.